Nova MD vs Enhance MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Nova MD
Best for lowest 3-month compounded pricing with an explicit microdose programStarting at $125/mo
Enhance MD
Best for lab-monitored compounded GLP-1 with mandatory video visitStarting at $49/mo
Side-by-Side Comparison
| Feature | Nova MD | Enhance MD |
|---|---|---|
| Overall Score | 7.2/10 | ✓8.6/10 |
| Starting Price | $125/mo | ✓$49/mo |
| Editorial Rating | 3.6 ★ /5 | ✓4.3 ★ /5 |
| Features | ✓8 features | 6 features |
| States Available | 0 | ✓39 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | ✓ Yes | — |
| FDA Warnings | None | None |
Pros & Cons
Nova MD
Pros
- ✓On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
- ✓$125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
- ✓$50 off first tirzepatide order shown publicly
- ✓Explicit microdose / low-dose program for both semaglutide and tirzepatide
- ✓Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1
- ✓FSA/HSA eligible and cancel-anytime billing with same-day doctor review
Cons
- ✗Legal entity name and state of incorporation not disclosed
- ✗Compounding pharmacy not named — only 'accredited facilities'
- ✗LegitScript certification not confirmed (only 'Licensed US Providers' claims)
- ✗Per-state availability not listed
- ✗Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic
- ✗Lab work and ongoing monitoring aren't clearly addressed
- ✗Patient count (1,241+) is an unverified marketing claim
Enhance MD
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Low first-month intro pricing: $49 Core, $99 Advanced, $189 Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro pricing resets to full tier rate after 30 days — the $49/$99/$189 figures aren't ongoing cost
Our Verdict
Enhance MD edges out Nova MD with a higher overall score of 8.6/10 and is particularly strong for lab-monitored compounded GLP-1 with mandatory video visit. Nova MD remains a solid alternative, especially if you're looking for lowest 3-month compounded pricing with an explicit microdose program.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Nova MD and Enhance MD head-to-heads in the same category.
- Nova MD vs CoreAge Rx
- Nova MD vs TrimRx
- Nova MD vs Amazon One Medical
- Enhance MD vs NovoCare Pharmacy
- Enhance MD vs Vytora Health
- Enhance MD vs Noom Med
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.